Loading clinical trials...
Loading clinical trials...
A Phase 1b/2, Open-Label, Dose-Finding and Proof of Concept Study of Nenocorilant in Combination With Anti-Programmed Cell Death/(Ligand) 1 in Patients With Advanced Solid Malignancies
Conditions
Interventions
Nenocorilant 200 mg
Nenocorilant 300 mg
+2 more
Locations
4
United States
Site 03
Los Angeles, California, United States
Site 04
Grand Rapids, Michigan, United States
Site 01
San Antonio, Texas, United States
Site 02
West Valley City, Utah, United States
Start Date
January 16, 2026
Primary Completion Date
September 1, 2026
Completion Date
January 1, 2027
Last Updated
April 3, 2026
NCT03206060
NCT06608446
NCT07541924
NCT07536087
NCT04895709
NCT06190899
Lead Sponsor
Corcept Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions